New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export MRK’s income statement to Excel — free account
Merck & Co., Inc.
MRKHealthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −12.1%
- Free cash flow
- −19.3%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
134.93
2.19
+1.65%
Follow MRK
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $14.7B covered $11.4B of dividends and buybacks. Cash fell by $8.6B. What is a cash flow statement?
- Free cash flow
- $14.7B 78.8% of operating cash flow
- Returned to shareholders
- $11.4B 77.4% of free cash flow
- Debt, net
- $12.7B borrowed
- Change in cash
- −$8.6B over the period
| Operating cash flow | 18.7 |
|---|---|
| Capital expenditures | −4.0 |
| Free cash flow | 14.7 |
| Acquisitions, net | −25.3 |
| From investments, net | +1.2 |
| Dividends | −8.4 |
| Buybacks, net | −3.0 |
| Debt raised, net | +12.7 |
| Other | −0.6 |
| Change in cash | −8.6 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $16.5B | $17.9B | $20.0B | $18.7B |
| Capex | −$4.1B | −$3.8B | −$3.9B | −$4.0B |
| Free cash flow | $12.4B | $14.1B | $16.1B | $14.7B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
18,263.00 | 8,935.00 | 3,169.00 | 2,449.00 |
Depreciation & Amortization |
5,838.00 | 6,251.00 | 6,715.00 | 7,344.00 | |
Non Cash Items (Other) |
(1,164.00) | 7,159.00 | 12,272.00 | 12,011.00 | |
Accounts Receivable Change |
(3,126.00) | — | — | — | |
Change in inventories |
(2,992.00) | — | — | — | |
Accounts Payable Change |
(377.00) | — | — | — | |
Change in payables and accrued liability |
(2,436.00) | — | — | — | |
Income tax paid |
1,754.00 | — | — | — | |
Change in other assets and liabilities |
(3,112.00) | (1,013.00) | 1,669.00 | 426.00 | |
Other operating activities |
511.00 | 422.00 | 6.00 | 337.00 | |
Operating Cash Flow |
16,472.00 | 17,890.00 | 19,967.00 | 18,703.00 | |
Capital expenditures |
(4,112.00) | (3,775.00) | (3,904.00) | (3,957.00) | |
Net Aquisitions |
(13,389.00) | (22,168.00) | (24,665.00) | (25,293.00) | |
Short Term Investments Change (Net) |
471.00 | 236.00 | 1,402.00 | 1,232.00 | |
Other investing activities |
(58.00) | (104.00) | (131.00) | (314.00) | |
Investing cash flow |
(13,741.00) | (22,464.00) | (27,296.00) | (28,332.00) | |
Repayment/Issuance of Debt (Net) |
11,377.00 | 13,798.00 | 18,688.00 | 12,727.00 | |
Equity Repurchase (Common, Net) |
(4,992.00) | (4,564.00) | (3,945.00) | (3,042.00) | |
Dividends Paid (Total) |
(8,176.00) | (8,231.00) | (8,298.00) | (8,366.00) | |
Other financial activities |
(131.00) | (151.00) | (275.00) | (219.00) | |
Financing cash flow |
(1,922.00) | 852.00 | 6,170.00 | 1,100.00 | |
Exchange Rate Adjustment |
563.00 | 388.00 | (23.00) | (79.00) | |
Change in Cash |
1,372.00 | (3,334.00) | (1,182.00) | (8,608.00) | |
Beginning Cash |
13,318.00 | 14,690.00 | 14,690.00 | 14,690.00 | |
Ending Cash |
14,690.00 | 11,356.00 | 13,508.00 | 6,082.00 | |
Stock Based Compensation |
820.00 | 810.00 | 892.00 | 1,057.00 | |
Dividends Paid (Common) |
(8,176.00) | (8,231.00) | (8,298.00) | (8,366.00) | |
Assets Liabilities Change (Total) |
(6,976.00) | (4,877.00) | (2,195.00) | (3,438.00) | |
Investments Change (Net) |
471.00 | 236.00 | 1,402.00 | 1,232.00 | |
Issuance/Purchase of Shares |
(4,992.00) | (4,564.00) | (3,945.00) | (3,042.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026